Options
使用甲型胎兒蛋白及乙型人類絨毛膜激素之母血唐氏症篩檢的臨床實用性
Journal Volume
中山醫學雜誌 v14 n.1 p9-14
Date Issued
2010-07-28T08:57:12Z
Abstract
研究目的：評估使用甲型胎兒蛋白及乙型人類絨毛膜激素之母血唐氏症篩檢的臨床實用性。研究材料與方法：我們收集從1999年1月到2002年1月間，共3819個懷孕14-23週的孕婦，其血液中甲型胎兒蛋白及乙型人類絨毛膜激素做作唐氏症篩檢。若其危險性大於1/270，則施行羊膜穿刺，此外，我們另選467個未經唐氏母血篩檢的高齡產婦，直接施行羊膜穿刺。結果：本研究中，母血唐氏症篩檢的陽性預測值為零，也無法計算其敏感度。在高齡產婦直接施行羊膜穿刺群組中，有六個成陽性反應。結論：第二孕期母血唐氏症篩檢的臨床實用性或許不足。
Objective: To evaluate the usefulness of screening for Down's syndrome with dual maternal serum markers. Material and Methods: From Jan 1999 to Jan 2002, maternal serum α-fetoprotein (MSAFP) and β-human chorionic gonadotropin (β-hCG) were measured in 3,819 pregnant women. Gestational age ranged from 14 to 23 weeks. If levels of MSAFP and β-hCG indicated the risk of Down's syndrome exceeded 1:270, amniocentesis was performed. Another 467 patients underwent amniocentesis because of advanced maternal age and the absence of previous maternal serum screening. Results: In our series, the predictive value of a positive test was zero. No sensitivity data are available. Six patients referred for amniocentesis because of their age tested positive for Down's syndrome. Conclusion: Screening for Down's syndrome with MSAFP and β-hCG in the second trimester may not be efficient or valid.
Objective: To evaluate the usefulness of screening for Down's syndrome with dual maternal serum markers. Material and Methods: From Jan 1999 to Jan 2002, maternal serum α-fetoprotein (MSAFP) and β-human chorionic gonadotropin (β-hCG) were measured in 3,819 pregnant women. Gestational age ranged from 14 to 23 weeks. If levels of MSAFP and β-hCG indicated the risk of Down's syndrome exceeded 1:270, amniocentesis was performed. Another 467 patients underwent amniocentesis because of advanced maternal age and the absence of previous maternal serum screening. Results: In our series, the predictive value of a positive test was zero. No sensitivity data are available. Six patients referred for amniocentesis because of their age tested positive for Down's syndrome. Conclusion: Screening for Down's syndrome with MSAFP and β-hCG in the second trimester may not be efficient or valid.